Founded in 2018 and based on the CNRS campus in Montpellier, Womed develops intravaginal/intrauterine polymer-based treatments for women's health. Its FDA-approved device Womed Leaf is intended to prevent intrauterine adhesions and the company reports about 2,000 women helped to date with a target of 95,000 women treated per year by 2028. Eynia is an investigational, gynecologist-administered biodegradable polymer treatment for fibroids that blocks progesterone for three months before degrading, and is planned to enter phase II trials. Womed says it aims to expand into treatments for acute bleeding and endometriosis. The company employs ten people and works with a similar number of consultants, including Dr André Ulmann. Financially, Womed recently raised €5 million from institutional investors, is running €1 million in public crowdfunding, and had previously raised €6 million in 2024.

Total raised

$8M

Funding rounds

2

Latest round

Crowdfunding

Latest activity

Jul 2026